PortViewPortView
XDNA logo

Kelly CRISPR & Gene Editing Technology (XDNA) ETF Holdings & Analysis

ETFOther

$7.38-1.60%
1-year price historyRange $5.87 – $11.76
52-week range$7.38
$5.87$11.83

What XDNA does

The fund employs a passive investment strategy, aiming to replicate the total return performance of its benchmark index. This index is rule-based, comprising equities or their corresponding depositary receipts from companies involved in the entire spectrum of DNA Modification Technology, including its invention, advancement, production, operation, provision, distribution, ownership, maintenance, licensing, leasing, or franchising. A minimum of 80% of the fund's net assets are dedicated to enterprises focused on DNA Modification Technology. This is a non-diversified fund.

Fund profile

Category
Other
AUM
$2.58M
Holdings
1
52-week high
$11.83
52-week low
$5.87

Top holdings

HoldingWeight
Cash & Other100.00%

Sector allocation

Healthcare100.00%

Geographic allocation

Other100.00%

PortView Portfolio Insights

PortView analyzes how XDNA fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze XDNA in PortView →

Related securities

Related stocks

Frequently asked questions

What does XDNA track?
XDNA is the Kelly CRISPR & Gene Editing Technology ETF, a Other ETF.
What is the expense ratio of XDNA?
Expense ratio data for XDNA is shown on the page when available from our data provider.
What are the largest holdings in XDNA?
Top holdings include Cash&Other.
How can PortView analyze XDNA overlap with other ETFs?
PortView computes the holdings overlap between XDNA and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.